Head to Head Analysis: Keryx Biopharmaceuticals (KERX) & Aerie Pharmaceuticals (AERI)

Keryx Biopharmaceuticals (NASDAQ: KERX) and Aerie Pharmaceuticals (NASDAQ:AERI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Keryx Biopharmaceuticals and Aerie Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keryx Biopharmaceuticals 0 4 1 0 2.20
Aerie Pharmaceuticals 0 1 12 0 2.92

Keryx Biopharmaceuticals currently has a consensus target price of $7.00, indicating a potential upside of 50.54%. Aerie Pharmaceuticals has a consensus target price of $72.46, indicating a potential upside of 21.27%. Given Keryx Biopharmaceuticals’ higher probable upside, equities research analysts clearly believe Keryx Biopharmaceuticals is more favorable than Aerie Pharmaceuticals.

Profitability

This table compares Keryx Biopharmaceuticals and Aerie Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Keryx Biopharmaceuticals -323.92% -10,954.62% -66.21%
Aerie Pharmaceuticals N/A -86.87% -41.89%

Risk and Volatility

Keryx Biopharmaceuticals has a beta of 4.94, suggesting that its stock price is 394% more volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Insider & Institutional Ownership

64.8% of Keryx Biopharmaceuticals shares are owned by institutional investors. 2.6% of Keryx Biopharmaceuticals shares are owned by insiders. Comparatively, 9.4% of Aerie Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Keryx Biopharmaceuticals and Aerie Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Keryx Biopharmaceuticals $31.98 million 17.33 -$161.09 million ($1.50) -3.10
Aerie Pharmaceuticals N/A N/A -$99.05 million ($3.35) -17.84

Aerie Pharmaceuticals has lower revenue, but higher earnings than Keryx Biopharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than Keryx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Aerie Pharmaceuticals beats Keryx Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit